Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 2/20 | 0.38 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219603 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL17974957 | 0.84 | MEN1 (0.47) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL4423507 | 0.83 | MEN1 (0.46) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL1624562 | 0.83 | MEN1 (0.50) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL6295798 | 0.83 | MLYCD (0.48) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL17974960 | 0.82 | MEN1 (0.45) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL29376714 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL572741 | 0.81 | ALDH1A1 (0.59) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL5435586 | 0.81 | MEN1 (0.44) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL9298402 | 0.80 | MAPT (0.42) | SMN1; SMN2MEN1KMT2AALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268525-B1 | MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING N-CYCLIC P2 MOIETIES | SCHERING CORP (US) | 2008-12-31 | — | — | EP | disclosed |
| US-6914122-B2 | Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties | SCHERING CORPORATION (US) | 2005-07-05 | — | — | US | disclosed |
| US-6846802-B2 | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties | SCHERING CORPORATION (US) | 2005-01-25 | — | — | US | disclosed |
| US-20020107181-A1 | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties | SCHERING CORPORATION | 2002-08-08 | — | — | US | disclosed |
| US-20020016294-A1 | Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties | SCHERING CORPORATION | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016294-A1 | Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties | PRSS3, HPN, DPP3 | SMN1; SMN2 2188/4885MEN1 4509/4885KMT2A 3306/4885 |
| US-20020107181-A1 | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties | HPN, TMPRSS15, HAVCR2 | SMN1; SMN2 3087/4885MEN1 4279/4885KMT2A 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.